Rusfertide improved hematocrit management in sufferers with polycythemia vera within the part 3 VERIFY trial, decreasing phlebotomy want and displaying a positive security profile.
Amongst phlebotomy-dependent sufferers with polycythemia vera, the addition of rusfertide to standard-of-care therapy reportedly elicited encouraging responses in comparison with placebo plus standard-of-care therapy.
Optimistic topline outcomes from the part 3 VERIFY examine have been introduced in a information launch issued by Protagonist Therapeutics and Takeda.
Rusfertide, described within the information launch as a first-in-class investigational hepcidin mimetic peptide therapeutic, has already acquired Orphan Drug designation and Quick Monitor designation from the Meals and Drug Administration (FDA), in response to the businesses.
Based on the information launch, 77% of sufferers handled with rusfertide confirmed a scientific response to therapy, in comparison with 33% of sufferers who acquired placebo, throughout weeks 20 to 32 of the examine. A response was outlined because the absence of phlebotomy eligibility.
Glossary:
Orphan Drug designation: a designation issued by the FDA to a drug or organic product to stop, diagnose or deal with a uncommon illness or situation, qualifying sponsors for incentives corresponding to tax credit, exemption from charges and a possible window of market exclusivity, in response to the FDA.
Quick Monitor designation: a course of designed to facilitate the event, and expedite the evaluate of medicine to deal with severe situations and fill an unmet medical want, as a way to get new medicine to sufferers sooner, in response to the FDA.
Many sufferers with polycythemia vera, the information launch famous, are at elevated threat for life-threatening cardiovascular and thrombotic occasions and should must frequently endure phlebotomy — described as a technique of eradicating blood to handle elevated ranges of hematocrit, or the share of pink blood cells within the blood — and cytoreductive therapies.
Rusfertide, in response to the Nationwide Most cancers Institute, mimics endogenous hepcidin, a protein primarily produced in hepatocytes within the liver and will increase hepcidin ranges. The drug may fit to normalize iron ranges.
There was a imply of 0.5 phlebotomies per affected person within the rusfertide arm of the VERIFY trial versus 1.8 phlebotomies per affected person within the placebo arm in weeks 0 to 32, in response to the information launch, which additional acknowledged that hematocrit management and patient-reported outcomes have been additionally achieved with statistical significance.
The businesses additionally famous that rusfertide was discovered to be nicely tolerated within the trial, with no new security alerts noticed. Nearly all of unwanted side effects have been grade 1 (gentle) to 2 (reasonable) injection web site reactions, and all severe unwanted side effects have been discovered to not be associated to the drug. Moreover, there was no proof of elevated most cancers threat amongst sufferers handled with rusfertide versus those that acquired placebo.
“The optimistic outcomes of the part 3 VERIFY examine… present compelling proof of the potential for rusfertide as a first-in-class erythrocytosis-specific agent to handle unmet medical wants in sufferers with PV who’re unable to realize enough hematocrit management regardless of commonplace of care remedies,” mentioned Dr. Arturo Molina, Chief Medical Officer of Protagonist. “We plan to submit extra particulars of those promising outcomes for presentation at upcoming medical conferences in 2025. We’re immensely grateful to the sufferers, examine workers and principal investigators who made the VERIFY examine attainable.”
“We’re inspired by these outcomes and excited concerning the potential of rusfertide to assist sufferers dwelling with [polycythemia vera]. These sufferers could expertise a excessive therapy burden, and extreme signs can affect their high quality of life,” mentioned Dr. Andy Plump, President of R&D at Takeda. “We’re deeply dedicated to bringing extra therapy choices to these dwelling with blood cancers, together with myeloid cancers corresponding to PV.”
“The totality of spectacular scientific knowledge thus far exhibits that rusfertide has the potential for significant optimistic affect on the lives of sufferers with PV,” mentioned Dinesh V. Patel, President and Chief Government Officer at Protagonist. “We stay up for working with our accomplice, Takeda, to submit our findings to the regulatory businesses. At present’s examine outcomes additionally mark a essential inflection level in Protagonist’s decade lengthy journey within the hepcidin program and additional validates our platform and experience in innovating extremely differentiated peptide-based medicines to meet unmet medical wants.”
The part 3 VERIFY trial is a three-part trial learning rusfertide amongst 293 sufferers with polycythemia vera over 156 weeks. Based on its itemizing on clincialtrials.gov, the trial has an estimated examine completion date of June 2025.
Polycythemia vera, in response to the Mayo Clinic, is a sort of blood most cancers that causes a affected person’s bone marrow to make too many pink blood cells. These cells can, in flip, thicken sufferers’ blood and gradual its move, which can result in points corresponding to blood clots.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
